A healthcare-focused venture capital firm with a team grounded in biomedical training and industry experience manages both local currency and USD-denominated funds and invests across early and growth stages. The firm has an established track record of investing in companies across multiple financing rounds and geographies, including Asia, North America, and Europe. The firm maintains a strong conviction in long-term growth opportunities within the global healthcare sector, particularly in cross-border innovation.
The firm invests broadly across therapeutics, medical devices, diagnostics, healthcare IT, and medical services. Within therapeutics, the firm has invested across a range of indications such as oncology, infectious diseases, and autoimmune disorders, covering multiple modalities including small molecules, biologics, and gene-based therapies. The firm also evaluates device and imaging technologies, as well as opportunities in bioinformatics, research tools, and adjacent areas such as animal health. Therapeutic investments typically begin at preclinical stages, while device investments are often made prior to commercialization.
From a company and management team perspective, the firm does not impose strict requirements and remains open to partnering with a wide range of teams and opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment